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Abstract
Background: Familial partial lipodystrophy (Dunnigan) type 3 (FPLD3, Mendelian Inheritance in
Man [MIM] 604367) results from heterozygous mutations in PPARG encoding peroxisomal
proliferator-activated receptor-γ. Both dominant-negative and haploinsufficiency mechanisms have
been suggested for this condition.
Methods: We present a Canadian FPLD3 kindred with an affected mother who had loss of fat on
arms and legs, but no increase in facial, neck, suprascapular or abdominal fat. She had profound
insulin resistance, diabetes, severe hypertriglyceridemia and relapsing pancreatitis, while her pre-
pubescent daughter had normal fat distribution but elevated plasma triglycerides and C-peptide and
depressed high-density lipoprotein cholesterol.
Results: The mother and daughter were each heterozygous for PPARG nonsense mutation Y355X,
whose protein product in vitro was transcriptionally inactive with no dominant-negative activity
against the wild-type receptor. In addition the mutant protein appeared to be markedly unstable.
Conclusion: Taken together with previous studies of human PPARG mutations, these findings
suggest that PPAR-γ deficiency due either to haploinsufficiency or to substantial activity loss due to
dominant negative interference of the normal allele product's function can each contribute to the
FPLD3 phenotype.
Background
Dunnigan-type familial partial lipodystrophy (FPLD), a
genetically heterogeneous condition with at least three
subtypes, is considered to be a monogenic model of the
common "metabolic syndrome" [1]. FPLD subtype 2
(FPLD2, MIM 151660) results from mutations in nuclear
lamin A/C encoded by LMNA (MIM 151330), and FPLD
subtype 3 (FPLD3, MIM 604367) results from mutations
in peroxisome proliferator-activated receptor-γ encoded
by PPARG (MIM 601487) [1]. The FPLD phenotype is
characterized by redistribution of fat stores – lipoatrophy
of extremities and gluteal region often with lipohypertro-
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phy involving the face and in central/visceral adipose
stores – together with clinical metabolic disturbances such
as hyperlipidemia, hypertension and diabetes [2]. Careful
phenotypic – or "phenomic" – analysis suggested that fat
redistribution is more extreme in FPLD2 compared to
FPLD3, but that metabolic disturbances are greater in
FPLD3 compared to FPLD2 [1-3]. Thus, fat loss is proba-
bly a key mechanism that contributes to the development
of metabolic complications in both FPLD subtypes, but
the more severe clinical features in FPLD3 suggest that
PPARG mutations may have additional direct effects.
Indeed, an independent direct effect of the dominant neg-
ative human PPARG P467L mutation – induction of
hypertension – was recently demonstrated in an animal
model [4,5].
Certain PPARG missense mutations in FPLD3 – such as
V290M and P467L – appear to act through a dominant
negative mechanism, in which the mutant allele product
is expressed and then interferes with the function of the
product of the wild-type allele, resulting in markedly
depressed net receptor activity [6,7]. In contrast, the heter-
ozygous PPARG missense mutation F388L in FPLD3 does
not act through a dominant negative mechanism; it
appears simply to have diminished transactivation capac-
ity, with no obvious effect on the wild-type allele product,
resulting in effective "haploinsufficiency" from depressed
but not absent receptor activity [8]. Furthermore, the
recently described heterozygous PPARG -14A>G promoter
variant in FPLD3 is associated with no coding sequence
change, and only a simple reduction in promoter activity
[9], again suggesting that haploinsufficiency but not com-
plete deficiency of PPAR-γ activity as the basis of disease
among affected heterozygotes. We now present a Cana-
dian FPLD3 family with a novel PPARG nonsense muta-
tion whose disease mechanism appears to be
haploinsufficiency rather than dominant negative.
Methods
DNA sequence analysis
The study received approval from the University of West-
ern Ontario Ethics Review Panel (protocol 07920E) and
all subjects gave informed consent to participate. DNA
sequencing initially showed no mutation in LMNA [4].
We amplified and sequenced the 6 exons of PPARG plus
>100 nucleotides at each intron-exon boundary, and
~700 bp of the promoter. Rapid, allele-specific genotyp-
ing methods were then developed for each mutation. For
the Y355X mutation genotype, we amplified the 603 bp
fragment containing exon 5 using primers 5' TTC ACT
GTG AGT TAG AAA TC and 3' CAA TGC AGA CTA ACA
CTA AGG. This was followed by electrophoresis in 2%
agarose, gel purification and ddNTP extension (SnaPShot,
PE Applied Biosystems, Mississauga, ON) with primer 5'
AAG AGC CTG CGA AAG CCT TT, and analysis on a Prism
377 DNA Sequencer (PE Applied Biosystems, Mississauga,
ON). Genomic DNA from 260 healthy Caucasian subjects
was studied, permitting 95% power to exclude a mutation
frequency ≥1% in the healthy population (two-tailed
alpha<0.05).
PPARγ clones and transcription assays
A cDNA encoding full-length human PPARγ1 was cloned
into the eukaryotic expression vector pcDNA4/HisMax-
TOPO (Invitrogen, Carlsbad, CA). The Y355X mutation
was introduced into this clone using the Quick-Change
mutagenesis kit (Stratagene, La Jolla, CA) by changing the
tyrosine codon (TAC) to a stop codon TAG. Both the wild-
type (WT) and mutant clones were fully sequenced. Initial
experiments demonstrated that transfection of the Y355X
PPARγ clone resulted in the production of a small amount
of full-length PPARγ protein, presumably generated by
inefficient translation termination at the 355X stop
codon. To eliminate this contaminating wild-type PPARγ,
which would compromise interpretation of results, a sec-
ond construct was generated in which all of the PPARγ
sequences down-stream of the 355X codon were deleted
from the plasmid. All of the transcription assays were car-
ried out with this construct. For transcription assays,
NIH3T3 mouse fibroblasts were grown in 96-well plates
(5.5 × 103 cells/well) in DMEM + 10% fetal calf serum.
Cells were transfected with the either WT or Y355X
mutant PPARγ expression plasmid, 1 ng of a β-galactosi-
dase control plasmid and 35 ng of the PPAR-dependent
luciferase reporter pFATP-Luc (three copies of the mouse
FATP gene PPRE inserted upstream of the minimal thymi-
dine kinase promoter). Cells were transfected for 4 h with
Lipofectamine-plus (Invitrogen, Carlsbad, CA) and then
treated with DMSO or the indicated amount of rosiglita-
zone for 16 h. Luciferase and β-galactosidase activities
were measured in cell extracts using the Dual-light assay
system (ABI, Foster City, CA) and a 96-well luminometer
(Berthold Technologies, Bad Wildbad, Germany). Trans-
fections were performed in triplicate.
Western analysis of wild-type and mutant PPARγ
To examine protein expression of PPARγ, a FLAG epitope
tag was added to the N-termini of WT and Y355X cDNAs
and both were transferred into the eukaryotic expression
vector pTRE-shuttle2 (BD Biosciences Clontech, Palo
Alto, CA). NIH3T3 cells (1.0 × 106 cells/well of a 6-well
plate) were transfected with the indicated amounts of
PPARγ expression plasmid, and 1 ng of a cyan fluorescent
protein-expressing plasmid pECFP-N1 as a control. After
20 h, cells were washed once in phosphate-buffered saline
(PBS) and then lysed in a buffer supplemented with 1%
Triton X-100, 50 mM HEPES, 150 mM NaCl, 1 mM EDTA,
30 mM NaF and 1 mM Na3VO4. Protein concentration
was determined by Bradford assay (Bio-Rad), and equal
amounts of protein were analyzed by SDS gel electro-
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phoresis. Western blots were performed by using mono-
clonal anti-FLAG-M2-peroxidase (HRP) conjugated
antibody (Sigma, St. Louis, MO).
Results
Subjects' medical histories and clinical studies
Subject II-5 (Figure 1). A 45 year-old woman was referred
for severe hypertriglyceridemia with relapsing pancreati-
tis. She had noted muscular legs and lower arms begin-
ning in adolescence. Menarche was at age 12 and periods
were regular. Type 2 diabetes mellitus and hypertriglycer-
idemia were diagnosed during her third pregnancy at age
33. Diabetes was treated with oral agents alone until age
40 when insulin was added. Control of both glycemia and
hypertriglyceridemia has been difficult, with triglycerides
>100 mmol/L at times and recurrent eruptive xanthomata
and pancreatitis. A five-month trial of pioglitazone 15 mg
daily resulted in a decrease in glycated haemoglobin
(HbA1c) from 12.1 to 7.6%, and in triglycerides from
66.4 to 7.3 mmol/L, but this was later discontinued due to
fluid retention. She had no history of hypertension. Phys-
ical examination revealed normal blood pressure, BMI 30
kg/m2, waist circumference 90 cm, and small eruptive
xanthomata over her elbows. Subcutaneous fat was mark-
edly diminished in her arms below the distal humerus
and in her buttocks, thighs, and calves, with prominent
arm and leg musculature. Facial, neck, suprascapular and
abdominal fat distribution was normal. She had no buf-
falo hump, acanthosis nigricans or phlebectasia. Abdom-
inal ultrasound showed an enlarged fatty liver and
enlarged spleen. Dual X-ray absorptiometry scan revealed
total body fat of 19.9% (within the normal female range),
but with decreased fat on the limbs, particularly the legs at
14%. Figure 2 shows a computed tomographic scan of the
legs of the proband and a normal subject; the proband
had a relative paucity of fat. Measurements in fasting
plasma included: glucose 14.4 mmol/L; HbA1c 10.1%
(normal 4.3–6.1%); insulin 26.3 mU/L (normal 5.0–
20.0); C-peptide 3.69 nmol/L (normal 0.30–1.32).
Plasma concentrations of total cholesterol and triglycer-
ides were 14.7 and 49.6 mmol/L; high-density lipoprotein
(HDL) and low-density lipoprotein (LDL) cholesterol
were not determined. Serum alanine transaminase was 21
U/L (normal <50 U/L). APOE genotype was normal (E3/
E3). Lipoprotein lipase activity was slightly depressed at
79 nmol/min/ml (normal >90 nmol/min/ml). Triglycer-
ides varied between 9.1 and 59.4 mmol/L despite treat-
ment with fenofibrate 200 mg and salmon oil 6 g daily.
Plasma glucose remained high despite taking >2 U/kg
insulin daily and metformin 500 mg TID. A five-day trial
of octreotide 100 µg TID to ameliorate abdominal pain
reduced plasma C-peptide levels to <1 nmol/L and insulin
to the normal range, but did not reduce fasting or post-
prandial glucose levels and produced abdominal bloat-
ing. Genomic DNA sequence analysis of the LIPE gene
encoding lipoprotein lipase showed no mutations.
A Canadian multigenerational FPLD3 kindredFigure 1
A Canadian multigenerational FPLD3 kindred. Darkened symbols indicate affected individuals, each of whom was later 
confirmed to be heterozygous for the respective PPARG nonsense mutation. Dots inside white symbols indicate normal PPARG 
genotype. Subject identification number and age in years are shown below the appropriate symbols.
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Subject III-3 (Figure 1). The 12 year-old daughter of sub-
ject II-5 was assessed for combined hyperlipidemia. She
was born at 33 weeks' gestation, during a pregnancy that
had been complicated by pre-eclampsia, diabetes and
hypertriglyceridemia. At age 3 months, she was diagnosed
with a patent ductus arteriosus with pulmonary branch
stenosis and incomplete right bundle branch block. She
had poor growth and difficulty feeding as an infant. She
was first noted to have elevated triglycerides and choles-
terol at age 5 that were treated only with dietary advice.
She required several corrective surgeries for strabismus,
the most recent at age 12. There was no history of pancre-
atitis or eruptive xanthomata. Height and weight at age 12
1/2 years were 153 cm (25–50th percentile for age and sex)
and 45.4 kg (50th percentile for age and sex), respectively.
She had a broad forehead with deep-set eyes, triangular
facies and a narrow pointed chin. Examination of the
chest, heart, and musculoskeletal systems was unremark-
able, and there was no acanthosis nigricans or phlebecta-
sia. She had a normal distribution of subcutaneous fat,
with no loss of fat over the arms, buttocks, or legs, and no
increase in face, neck, suprascapular or abdominal fat.
Measurements in fasting plasma revealed: glucose 5.0
mmol/L; insulin 18.2 mU/L (normal 5.0–20 mU/L); C-
peptide 1.64 nmol/L (normal 0.30–1.32 nmol/L); total
cholesterol 5.26 mmol/L (normal 3.2–4.4 mmol/L for
age), triglycerides 1.79 mmol/L (normal 0.4–1.3 mmol/
L); HDL cholesterol 0.92 mmol/L (normal 1.0–1.8
mmol/L); and LDL cholesterol 3.52 (normal 1.6–2.8
mmol/L).
DNA sequence analysis
Subjects II-5 and III-3 were each found to be heterozygous
for a nonsense mutation (single nucleotide base change),
that predicted a premature termination signal rather than
the wild-type (WT) tyrosine at codon 355 (Figure 3). This
mutation was absent from 5 non-FPLD3 first-degree rela-
tives of subject II-5 (namely subjects I-2, II-2, II-4, III-1
and III-2). The mutation was absent from the genomes of
260 healthy control subjects.
Transcriptional activity of PPARγ Y355X
To establish experimental conditions that generated equal
amounts of the Y355X mutation, epitope-tagged versions
of the WT and mutant PPARγ clones were transfected into
NIH3T3 cells. Western analysis of extracts from these cells
demonstrated that much less Y355X mutant protein was
produced from the same amount of transfected DNA sug-
gesting that the mutant receptor was significantly less sta-
ble than the wild-type receptor (Figure 4A).
Approximately 15 times more Y355X than wild-type DNA
was needed to generate equal amounts of the two PPARγ
proteins. Using these conditions, the transcriptional activ-
ity of the Y355X PPARγ mutant was assessed by transient
transfection of (non-epitope tagged) PPARγ expressing
plasmids into NIH3T3 cells and measuring luciferase
activity from a PPAR responsive reporter. Under these
conditions the Y355X mutation did not display any tran-
scriptional activity at any dose of the ligand rosiglitazone
(Figure 4B).
To determine if the Y355X receptor had dominant-nega-
tive activity against WT PPARγ, a mixing experiment was
performed in which WT and mutant receptors were co-
transfected into NIH3T3 cells. In the absence of ligand,
the transcriptional activity of the combination of 1 ng of
WT and 15 ng of Y355X DNA (equal protein amounts)
was similar to 1 ng of WT receptor alone (Figure 5A). Like-
wise, in the presence of a saturating amount of ligand, the
presence of an equal amount of Y355X protein did not
reduce the activity of co-transfected WT PPARγ. These
results indicate that the Y355X mutation does not have
dominant-negative activity against the WT receptor. This
was confirmed by further mixing experiments in which an
increasing amount of mutant or WT receptor was mixed
with a fixed amount of WT PPARγ (Figure 5B). While
increasing the amount of the wild-type receptor caused a
dose dependent increase in transcriptional activity (Figure
5B, open bars), the addition of increasing amounts of
Y355X PPARγ to a fixed amount of wild-type receptor had
no significant effect on transcription (Figure 5B, filled
bars). For comparison, the same experiment was con-
ducted with a PPARγ mutation (V290M) that has been
previously shown to have dominant-negative activity [6].
Increasing amounts of V290M PPARγ caused a dose-
dependent decrease in wild-type PPARγ transcriptional
Selected imaging studies from the FPLD3 subjectFigur  2
Selected imaging studies from the FPLD3 subject. 
Panel shows computed tomography cross-section of upper 
thigh of a normal individual and subject II-5, who had mark-
edly decreased subcutaneous fat on both extremities.
normal
PPARG
Y355X
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activity in this assay (Figure 5B, grey bars). Thus, PPARγ
receptors bearing the Y355X mutation do not possess any
dominant-negative activity against the wild-type PPARγ
receptor
Discussion
The principal novel findings of this study are: 1) identifi-
cation of a novel human PPARG nonsense mutation,
namely Y355X; 2) demonstration that heterozygosity for
Y355X is associated with partial lipodystrophy and meta-
bolic disturbances consistent with the FPLD3 phenotype;
and 3) evidence that the mechanism underlying the dis-
ease association in affected heterozygotes is haploinsuffi-
ciency rather than dominant negative interference of the
function of the normal allele product. The Y355X muta-
tion caused the complete inactivation of PPARγ transcrip-
tional activity and reduced the stability of the PPARγ
protein.
The Y355X nonsense mutation almost certainly creates
haploinsufficiency – a quantitative deficiency – for PPARγ
in affected FPLD3 subjects. PPARG Y355X (present in two
FPLD3 subjects) encodes a protein that is truncated by
~30% and shows no transcriptional activity. Furthermore,
the Y355X mutant receptor clearly does not display dom-
inant-negative activity against WT receptor in transfection
assays. The likelihood that this lack of dominant-negative
activity reflects the in vivo situation is supported by the
observation that the adult proband with Y355X had a ben-
eficial response to an average pharmacological dose of the
thiazolidinedione pioglitazone. Given the specificity of
this ligand for PPARγ, this observation suggests that there
is no interference of the normal allele product. The in
vitro results also indicate that the Y355X mutation signif-
icantly reduces the stability of the receptor, making it
likely that cells with one wild-type and one Y355X allele
(as occurs in these patients), would contain significantly
less mutant receptor compared to the wild-type protein.
Together, these findings strongly suggest that the PPARG
Y355X mutation acts via a haploinsufficiency mechanism.
The findings extend the range of heterozygous PPARG
mutations seen in FPLD3 [6-10]. Currently, most hetero-
zygous PPARG mutations (3/6 total heterozygous muta-
tions, namely -14A>G, F388L and Y355X) from most
affected subjects (8/12 total FPLD3 subjects), act via a
haploinsufficiency mechanism. The PPARG -14A>G
mutation within the promoter of the γ4 isoform (present
in two FPLD3 subjects) was associated with quantitative
loss of expression of the allele product, with no qualitative
abnormalities of the encoded protein [9]. PPARG F388L
(present in four FPLD3 subjects), a transactivation-defi-
cient missense mutation, was expressed at normal levels
and had no in vitro dominant negative interference with
the function of the normal allele [9]. The combined LOD
score for the linkage of these four heterozygous PPARG
haploinsufficiency mutations with the FPLD3 phenotype
in the three kindreds is 3.0 (maximum at 0% recombina-
tion), providing additional human genetic evidence for
causation.
Only two heterozygous germline PPARG mutations in
FPLD3, namely P467L (present in two FPLD3 subjects)
and V290M (present in one FPLD3 subject), were shown
by convincing in vitro studies to act through a dominant
negative mechanism [6,7]. The PPARG R425C mutation
(present only in one FPLD3 subject) has not yet been
functionally assessed in vitro [10]. Another nonsense
mutation in PPARG, namely A553∆AAATfs185, did not
show dominant negative interference of the WT allele,
and carriers of this mutation did not have FPLD3, but sim-
ple insulin resistance, which required double heterozy-
gosity with a truncation mutation in PPP1R3A for clinical
expression. Yet another PPARG missense mutation,
R115Q, was found in obese subjects without FPLD3; it
had defective phosphorylation of serine at position 114
and an apparent gain of function resulting in accelerated
differentiation of pre-adipocytes [11]. The PPARG muta-
tions in subjects without FPLD3 indicate the complexity
of the relationship between mutations in this gene and
clinical phenotypes, such as phenotype differences related
to differences in functional impact, and the requirement
Genomic DNA sequence electropherograms of hetero-zygous PPARG mutationFi ure 3
Genomic DNA sequence electropherograms of het-
erozygous PPARG mutation. The bottom electrophero-
gram tracing shows both alleles in subject II-5 from kindred 1 
(Y355X), compared to sequence from a healthy subject. The 
position of the mutation is indicated by the arrow. Normal 
nucleotide and amino acid sequence is shown above the wild 
type electropherogram tracing.
 5’ ATC ATT TAC ACA ATG 3’
 I I Y T M
 Y355X
PPARG Y355X
Proband genomic DNA
Wild type  genomic DNA
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for interactions with other genes before a phenotype is
expressed. The presence of a metabolic phenotype with-
out loss of subcutaneous fat in the pre-pubescent carrier of
Y355X suggests either some variation in penetrance of
PPARG mutations, or some influence of other genes acti-
vated in puberty that may affect the expression of the
Y355X mutation.
How might a quantitative relative loss-of-function muta-
tion in one PPARG allele contribute to adipose reparti-
tioning and insulin resistance in FPLD3? Quantitative
increases in activity as induced by pharmacological PPAR
agonism can enhance insulin sensitivity and anabolically
influence adipose tissue [3]. But heterozygous PPARγ-
deficient mice in which one allele has been deleted seem
to be less insulin resistant than their WT littermates
[12,13]. This suggests that an additional mechanism or
stress may be required to produce insulin resistance in
The Y355X mutant receptor does not inhibit the activity of wild-type PPARγFigure 
The Y355X mutant receptor does not inhibit the 
activity of wild-type PPARγ. (A) WT and Y355X recep-
tors (1 and 15 ng respectively) were transfected into NIH 
3T3 cells individually or in combination in the presence or 
absence of 5 µM rosiglitazone (Rosi). (B) NIH 3T3 cells were 
transfected with the combination of 1 ng of WT PPARγ and 
increasing amounts of either the WT (1–4 ng), the dominant/
negative mutant V290M (1–4 ng) or the Y355X mutant 
receptor (1–15 ng) as indicated. Data are normalized to the 
transcriptional activity of 1 ng of WT receptor and are pre-
sented as means ± SD (n = 3).
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Y355X mutation reduces PPARγ protein stability and tran-scriptional activityFigure 4
Y355X mutation reduces PPARγ protein stability and 
transcriptional activity. (A) Western blot of lysates from 
NIH 3T3 cells transfected with the indicated amount of plas-
mid expressing either FLAG tagged Y355X (fl355X) or wild-
type (flWT) PPARγ proteins. PPARγ was visualized with anti-
FLAG antibodies and ECFP produced from co-transfected 
plasmid (visualized with an anti-ECFP antibody) was utilized 
as a transfection and loading control. The numbers below the 
panel represent the density of each PPARγ-FLAG band nor-
malized to the ECFP band. Roughly equal amounts of mutant 
and WT protein expression were achieved by a 15 fold 
excess of transfected mutant over WT PPARγ DNA. (B) 
Rosiglitazone dose-response curves for WT and Y355X 
PPARγ in NIH 3T3 cells transfected with 1 ng of WT or 15 
ng of Y355X expression plasmids (non-FLAG-tagged ver-
sions) or 15 ng of empty vector, together with a PPAR 
responsive reporter construct (pFATP-luc) and a β-galactosi-
dase reference plasmid. Data are normalized to the WT vehi-
cle controls and are means ± SD (n = 3).
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human homologues of these animals. A simple quantita-
tive genetic deficiency of PPARγ might compromise the
ability of heterozygotes to express sufficient PPARγ, per-
haps creating a bottleneck at key stages of adipose differ-
entiation during development and adolescence. In
contrast to other direct effects of PPARG mutations on
other pathways and targets, a simple reduction in func-
tional activity resulting from the -14A>G, F388L and
Y355X mutations may be sufficient to produce a clinical
phenotype.
Interestingly, both subjects ascertained here were females.
Observations from the small numbers of PPARγ-deficient
individuals indicate that females may be more severely
affected than males [1-3,6-10]. Similar, between-sex dif-
ferences in phenotype severity were noted in FPLD2 due
to mutant LMNA [1]. But the anecdotal nature of the
between-sex differences in phenotypic severity in PPARγ-
deficiency and in partial lipodystrophy precludes specula-
tion regarding potential mechanisms. Ascertainment of
additional subjects and families and specific physiological
studies are required. In summary, we have found a rare
nonsense mutation causing reduced expression of PPARγ
in a proband with FPLD3.
Conclusion
The findings in this Canadian kindred extend the range of
PPARG mutations in FPLD3 and especially those that
likely operate through a haploinsufficiency mechanism.
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